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PGC1a is a key transcriptional coregulator of oxida-
tive metabolism and thermogenesis. Through a
high-throughput chemical screen, we found that
molecules antagonizing the TRPVs (transient re-
ceptor potential vanilloid), a family of ion channels,
induced PGC1a expression in adipocytes. In partic-
ular, TRPV4 negatively regulated the expression of
PGC1a, UCP1, and cellular respiration. Additionally,
it potently controlled the expression of multiple
proinflammatory genes involved in the development
of insulin resistance. Mice with a null mutation for
TRPV4 orwild-typemice treatedwith a TRPV4 antag-
onist showed elevated thermogenesis in adipose
tissues and were protected from diet-induced
obesity, adipose inflammation, and insulin resis-
tance. This role of TRPV4 as a cell-autonomous
mediator for both the thermogenic and proinflamma-
tory programs in adipocytes could offer a target for
treating obesity and related metabolic diseases.INTRODUCTION
Brown adipose tissue (BAT) is specialized for the efficient
dissipation of chemical energy in the form of heat. It does
this by having an exceptionally high mitochondrial content
and respiration that is uncoupled from ATP synthesis. This
uncoupling is mainly due to the presence of UCP1, a protein
that catalyzes proton leak across the inner mitochondrial
membrane. Brown fat is very prominent in rodents and human
infants, but the presence of substantial brown fat deposits in
adult humans has only recently been appreciated (Cypess96 Cell 151, 96–110, September 28, 2012 ª2012 Elsevier Inc.et al., 2009; van Marken Lichtenbelt et al., 2009; Virtanen
et al., 2009).
It is now known that there are two distinct kinds of brown
adipocytes. The classical type is exemplified by the interscapular
depot of rodents; these UCP1-expressing cells are derived from
a muscle-like lineage that expressed Myf5/Pax7 during earlier
development (Lepper and Fan, 2010; Seale et al., 2008).
UCP1-positive cells can also emerge in many white fat depots
under chronic exposure to cold or b-adrenergic stimulation
(Cousin et al., 1992; Ghorbani and Himms-Hagen, 1997; Guerra
et al., 1998; Himms-Hagen et al., 2000; Xue et al., 2005). These
cells do not come from a myf5-positive lineage (Seale et al.,
2008) and have been called beige or brite fat cells (Ishibashi
and Seale, 2010; Petrovic et al., 2010). The regulation of UCP1
and the broader thermogenic gene program in both types of
brown adipocytes has been studied in detail. Key transcriptional
regulators include FOXC2 (Cederberg et al., 2001), C/EBPb
(Karamanlidis et al., 2007), LXR (Korach-Andre´ et al., 2011),
PGC1a (Puigserver et al., 1998; Uldry et al., 2006), and
PRDM16 (Kajimura et al., 2009; Seale et al., 2007, 2008).
PGC1a was originally identified as a coactivator of PPARg
in the control of the UCP1 promoter in brown adipocytes
(Puigserver et al., 1998). Subsequent work has illustrated that it
binds to and coactivates many transcription factors (Handschin
and Spiegelman, 2006). PGC1a plays a key role in mitochondrial
biogenesis and oxidative metabolism in many tissues, linking
mitochondrial biogenesis to the extracellular and extraorganis-
mal environment. PGC1a gene expression is induced in brown
adipose tissue by cold exposure and by agents that activate
the b-adrenergic system.
The responsiveness of PGC1a gene expression to external
stimuli suggested that it might be possible to find chemical com-
pounds that increase PGC1a expression and function. This in
turn might be useful for the treatment of a variety of diseases
that would benefit from increased PGC1a or from increased
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Figure 1. Chemical Screen Identifies TRPVs as Negative Regulators of PGC1a Expression
(A and B) qPCR analysis of Pgc1amRNA in 3T3-F442A adipocytes after 24 hr treatment of CB1 antagonists (A) or TRPV1 antagonists (B). All chemicals were used
at 0.2, 2, and 20 mM, except AM251 (20 mM).
(C–E) Normalized mRNA expression of Trpv1-4 (C). aP2 (D) and Pgc1a (E) mRNA levels in adipocytes infected with scrambled (SCR), shTRPV1, shTRPV2, or
shTRPV4 lentivirus.
Data are presented as mean ±SD. See also Figure S1.mitochondrial activity (Handschin and Spiegelman, 2008).
Because elevated PGC1a in muscle plays an antidystrophic
and antiatrophic function, we previously screened for drugs
and drug-like molecules that elevate PGC1a in murine myotubes
(Arany et al., 2008). Several inhibitors of microtubules and
protein synthesis were identified as PGC1a inducers. This illus-
trated that screening for activators of PGC1a expression could
identify compounds capable of increasing mitochondrial action.
Conversely, when a screen for chemicals that could alter
mitochondrial function was carried out, an overlapping set of
regulators of PGC1a was uncovered (Wagner et al., 2008).
Unfortunately, none of these compounds had an activity/toxicity
ratio that was favorable for animal or human studies.
In this study, we have screened a chemical library for com-
pounds that could increase PGC1a gene expression in white
adipocytes. We show here that TRPV4, a member of a family
of chemically tractable ion channels, is a negative regulator of
PGC1a and the thermogenic gene program. Furthermore,
TRPV4 positively regulates a host of proinflammatory genes inwhite adipocytes. Genetic ablation and pharmacological inhibi-
tion of TRPV4 inmicemodulate both thermogenic and proinflam-
matory pathways in fat, resulting in a robust resistance to obesity
and insulin resistance.
RESULTS
A Chemical Screen Identifies TRPVs as Negative
Regulators of Pgc1a Expression
We performed a quantitative PCR-based chemical screen to
identify small molecules that can induce Pgc1a messenger
RNA (mRNA) expression in white adipocytes. Fully differentiated
3T3-F442A adipocytes were treated with a chemical library of
3,000 drugs and drug-like compounds for 20 hr; mRNA from
treated cells was then analyzed to quantify the expression of
Pgc1a (Figure S1 available online). AM-251, a cannabinoid
receptor 1 (CB1) antagonist, was identified as one of the primary
hits (Figure 1A). AM-251 is a structural analog of a well-known
CB1 antagonist, rimonabant (Lan et al., 1999), an antiobesityCell 151, 96–110, September 28, 2012 ª2012 Elsevier Inc. 97
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Figure 2. TRPV4 Negatively Regulates Oxidative Metabolism and Respiration in Adipocytes
(A) TRPV4 protein in 3T3-F442A adipocytes with shTRPV4 or shGFP. Adipose tissue lysate from WT and Trpv4/ mice was used as control.
(B) Intracellular Ca2+ rose in response to hypotonicity (220 mOsm, arrow) and to 100 nM GSK1016790A (arrowhead) only in cells with shGFP (n = 48), but not in
cells with shTRPV4 (n = 49).
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drug that was in clinical use in Europe. Although AM-251 is anno-
tated as a CB1 antagonist, two other CB1 antagonists, SLV319
and CAY10508, failed to induce Pgc1a at any dose tested (Fig-
ure 1A). Importantly, other molecular targets of AM251 or rimo-
nabant have been reported, including TRPV1 (De Petrocellis
et al., 2001; Zygmunt et al., 1999). As shown in Figure 1B, two
TRPV1 antagonists, AMG9810 and BCTC, increased Pgc1a
mRNA expression in adipocytes in a dose-dependent manner
(Figure 1B).
AMG9810 antagonizes TRPV1 but can also antagonize closely
related TRPVs, such as TRPV2, TRPV3, and TRPV4, at the
micromolar doses used here (Gavva et al., 2005). We therefore
compared themRNA expression of Trpv1-4 in 3T3-F442A adipo-
cytes. mRNAs encoding Trpv1, Trpv2, and Trpv4 were ex-
pressed in 3T3-F442A adipocytes, with Trpv4 being expressed
at the highest level (Figure 1C). To determine which of these
channels were regulating Pgc1a expression, we used small
hairpin RNA (shRNA)-mediated knockdown of each of the ex-
pressed TRPVs with lentiviral vectors (Figure S1B). None of the
shRNAs appeared to affect adipose differentiation per se, as
indicated by the similar expression of the adipose-selective
gene aP2 (Figure 1D). Pgc1a mRNA was strongly induced by
the shRNA against TRPV4; shRNA against TRPV1 also had
a small effect (Figure 1E). These functional data, along with the
fact that the expression of Trpv4 mRNA was ten times higher
than that of Trpv1 in these cells, strongly suggest that TRPV4
was the dominant TPRV family member regulating the induction
of Pgc1a mRNA by the chemical inhibitors.
TRPV4 Is a Negative Regulator of Oxidative Metabolism
and Respiration in Adipocytes
TRPV4 is a calcium-permeable ion channel that was first identi-
fied as an osmolality sensor (Liedtke et al., 2000; Strotmann
et al., 2000). Since then, many physical and chemical stimuli
have been shown to activate TRPV4, including heat, mechanical
stress, anandamide, arachidonic acid, and its derivatives (Ever-
aerts et al., 2010; Nilius et al., 2007). Adipose tissue was shown
to have one of the highest levels of Trpv4 mRNA expression
(Liedtke et al., 2000). We found that Trpv4 expression was higher
in white adipose tissues than in brown fat tissue (Figure S2A).
We used retroviral vectors expressing an shRNA against
TRPV4 or green fluorescent protein (GFP) to make stable cells
with altered TRPV4 expression for biochemical and bioenergetic
analyses. Again, the ectopic retroviral shRNA did not appear to
affect adipocyte differentiation per se (Figure S2B). We first
examined whether there were functional TRPV4 channels
present in 3T3-F442A adipocytes. TRPV4 protein was detected
by western blot (Figure 2A). In addition, we used Ca2+ imaging(C) Representative current-voltage plots of endogenous whole-cell Trpv4 curre
solution (gray) and upon stimulation with 100 nM GSK1016790A (black). Voltage
(D) Mean current densities at112mV and +88mV in adipocytes with shGFP (right
with GSK1016790A (black).
(E) Pgc1a and Ucp1 mRNA expression, with or without 100 nM norepinephrine.
(F) PGC1a protein.
(G) mRNA expression of mitochondrial components.
(H) Basal, uncoupled, and FCCP-stimulated oxygen consumption rates.
(I) mRNA expression of aP2, Pgc1a, Ucp1, and Cox8b after 48 hr treatment of 10
Data are presented as mean ±SD. See also Figure S2.to test for TRPV4 activity. Both hypotonicity and the TRPV4
agonist GSK1016790A (Thorneloe et al., 2008; Willette et al.,
2008) induced a TRPV4-dependent increase in intracellular
calcium in adipocytes (Figure 2B). Consistent with Ca2+ imaging
results, TRPV4 agonist evoked a TRPV4-like current in control
adipocytes, but not in cells expressing an shRNA against
TRPV4 (Figures 2C and 2D).
Pgc1amRNA expression was three times higher in adipocytes
expressing shRNA against TRPV4 compared to controls (Fig-
ure 2E). Increased PGC1a protein was confirmed by western
blot (Figure 2F). b-adrenergic signaling is important for the induc-
tion of PGC1a and its thermogenic targets; when cells were
exposed to norepinephrine, mRNA expression of Pgc1a and
Ucp1 was robustly increased in the TRPV4 knockdown cells
compared to controls (Figure 2E). PGC1a is known to drive the
expression of many genes involved in mitochondrial oxidative
phosphorylation, including cytochrome c (CytC) and the cyto-
chrome C oxidative (COX) subunits (CoxIII, Cox4il, Cox5b,
Cox7a, and Cox8b). We observed higher mRNA (Figure 2G)
and protein (Figure S2C) expression of these genes in TRPV4
knockdown adipocytes. These changes were dependent on
the induction of PGC1a, as the increased expression of these
genes was attenuated by expression of an shRNA against
PGC1a (Figure S2D).
The increased expression of Pgc1a, Ucp1, and other mito-
chondrial genes suggested that TRPV4 inhibition caused the
white adipocytes to develop brown-fat-like characteristics,
which we termed ‘‘browning’’ here. To determine the physiolog-
ical impact of this browning gene program, oxygen consump-
tion was measured in adipocytes. As shown in Figure 2H,
TRPV4 knockdown adipocytes showed increase in basal, un-
coupled, and FCCP-stimulated maximal respiration compared
to controls.
We next examined whether chemical activation of
TRPV4 would have the opposite impact on these pathways.
When added to 3T3-F442A adipocytes, the TRPV4 agonist
GSK1016790A repressed the expression of mRNAs encoding
Pgc1a, Ucp1, and Cox8b in a TRPV4-dependent manner (Fig-
ure 2I). Taken together, these data strongly suggest that
TRPV4 functions as a negative regulator of PGC1a and oxidative
metabolism in white adipocytes.
TRPV4 Positively Controls a Proinflammatory Gene
Program in Adipocytes
To fully understand the function of TRPV4 in adipocytes, micro-
array analysis was performed with mRNA from 3T3-F442A
adipocytes expressing shRNAs against TRPV4 or GFP. As ex-
pected, many genes whose expression was strongly increasednt measured in adipocytes with shGFP (right) and shTRPV4 (left) in Tyrode’s
ramp protocol (500 ms) shown in inset.
, n = 6) and shTRPV4 (left, n = 6) in Tyrode’s solution (gray) and upon stimulation
0 nM GSK1016790A.
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Figure 3. TRPV4 Controls Proinflammatory Gene Expression in Adipocytes
(A and B) qPCR analysis of mRNA-encoding chemokines/cytokines (A) and genes involved in proinflammatory pathways (B) in 3T3-F442A adipocytes with
shTRPV4 or shGFP.
100 Cell 151, 96–110, September 28, 2012 ª2012 Elsevier Inc.
were those involved in brown fat function (Table S1). Pgc1a was
one of the most highly regulated genes on these arrays.
Strikingly, many genes whose expression was decreased by
the TRPV4 knockdown were chemokines/cytokines or genes
related to proinflammatory pathways (Table S1). We further
analyzed the expression of 22 genes that are either highly regu-
lated by TRPV4 (from the array) or are known to be important
in adipose inflammation based on literature. Knockdown of
TRPV4 had a profound inhibitory effect on a whole array of
chemokines such as Ccl2 (Mcp1), Ccl3 (Mip1a), Ccl5 (Rantes),
Ccl7 (Mcp3), Cxcl1 (KC), Ccl8, Cxcl5, and Cxcl10 and cytokines
such as Il6, Saa3, and Thrombospondin (Figure 3A). A similar
effect was observed on the expression of other genes impor-
tant for inflammatory processes, such as Tlr2, Timp1, Socs3,
Socs5, Mmp2, Fas, and Vcam (Figure 3B). Conversely, mRNA
expression of Mip1a, Cxcl1, Il6, Timp1, and Tlr2 can be
induced by the TRPV4 agonist (Figure 3C). This effect is
specific and dependent on TRPV4, as shRNA against TRPV4
fully abolished the induction caused by the agonist (Figure 3C).
mRNA expression changes for other adipokines, such as Adi-
ponectin, Leptin, RBP4, and Resistin, were also observed
(Figure S3).
To determine whether these effects on gene expression re-
sulted in alterations in chemokine secretion, we measured levels
of secreted MCP1, MIP1a, CXCL1, IL6, and RANTES in culture
medium. Similar to what we observed at the mRNA level, the
concentrations of MCP1, MIP1a, CXCL1, IL6, and RANTES
were each reduced by more than 85% in the culture medium
from the TRPV4 knockdown adipocytes, as compared to
controls (Figure 3D). The TRPV4 agonist potently induced
MIP1a and IL6 secretion; the secretion of MCP1 was mildly
reduced. These data indicate a powerful role for TRPV4 in the
regulation of a proinflammatory pathway in adipocytes.
ERK1/2 Mediate Signal Transduction from TRPV4
We investigated the signaling pathways by which TRPV4 carries
out these functions in adipocytes. It has been reported that the
protein kinases ERK1/2 can be activated by TRPV4 signaling
(Li et al., 2009; Thodeti et al., 2009). We therefore examined
TRPV4 agonism and the activation of three mitogen-activated
protein (MAP) kinases that have been implicated in adipose
biology: ERK1/2, JNK1/2, and p38 MAPK. Addition of the
TRPV4 agonist to 3T3-F442A adipocytes caused a rapid phos-
phorylation of both ERK1/2 and JNK1/2 at sites known to reflect
activation of these kinases. In contrast, no activating phosphor-
ylation on p38 MAPK was detected with TRPV4 agonism,
whereas the b3-agonist CL316243 led to the expected p38
MAPK activation (Cao et al., 2001) (Figure 4A). The activation
of ERK1/2 appeared to be dependent on TRPV4 and the pres-
ence of extracellular calcium. The phosphorylations caused by
the TRPV4 agonist were largely attenuated by the shRNA against
TRPV4 or by the depletion of extracellular calcium; in contrast,(C) mRNA expression of Mcp1, Mip1a, Rantes, Mcp3, Il6, Cxcl1, Timp1, and Tlr2
(D) Protein concentrations of MCP1, MIP1a, CXCL1, IL6, and RANTES in culture
Data are presented asmean ±SD. *p < 0.05, **p < 0.01, and ***p < 0.001, comparin
cells treated with DMSO or GSK1016790A. See also Figure S3.the phosphorylations caused by TNFa were not affected
(Figure 4B).
Inhibitors of MEK1/2 (U0126) and JNK (SP600125) were used
to determine whether the activation of these two MAP kinases
was required for the key TRPV4-mediated gene regulation
events. Pretreatment of cells with U0126 and SP600125 blocked
the TRPV4 agonist-induced phosphorylation of ERK1/2 and
JNK1/2, respectively (Figure 4C). Interestingly, U0126 effectively
reversed the repression on Pgc1a caused by the agonist (Fig-
ure 4D). In contrast, SP600125 had only a small effect. Concor-
dantly, the induction of Mip1a and Cxcl1 by the TRPV4 agonist
was abolished by U0126; SP600125 had no effect. These data
strongly suggest that the ERK1/2 protein kinases mediate
much of the effect of TRPV4 activation on both the repression
of Pgc1a expression and the induction of many chemokines/
cytokines in adipocytes.
TRPV4-Deficient Mice Have Altered Expression of
Thermogenic and Proinflammatory Genes in Adipose
Tissue in a Cell-Autonomous Manner
To investigate the function of TRPV4 in adipose tissues in vivo,
we studied mice with a genetic deletion of Trpv4. These mice
are grossly similar to wild-type (WT) animals in morphology,
behavior, and breeding (Liedtke and Friedman, 2003). On
a chow diet, their body weight is indistinguishable fromWT litter-
mates (Figure 5A). In light of the effect of TRPV4 on ‘‘browning’’
and proinflammatory programs in white adipocytes, we exam-
ined gene expression in white adipose tissues from Trpv4/
and WT mice.
Subcutaneous (SubQ) adipose tissue has been shown to have
a greater thermogenic capacity than other white adipose tissues
(Barbatelli et al., 2010) and can significantly contribute to whole-
body energy homeostasis (Seale et al., 2011). Strikingly, SubQ
fat from Trpv4/ mice expressed 30-fold higher Ucp1 mRNA
and more UCP1 protein compared to controls (Figures 5B and
5D). A trend toward increased Pgc1a mRNA (Figure 5B) and
protein (Figure 5C) was also detected in Trpv4/ adipose
tissues, however, with substantial variability between individual
animals. These mice also have elevated mRNA levels for many
genes known to be enriched in BAT, such as Cidea, Cox4il,
and Cox8b (Figure 5B). In general, epididymal (EPI) fat has
a lower thermogenic capacity; nonetheless, mRNA levels for
Adrb3, Pgc1b, CytC, Cox4il, and Cox5awere significantly higher
in EPI fat from the Trpv4/ mice compared to controls
(Figure S4D).
We also measured the expression of proinflammatory
chemokines, which were identified from the analysis of TRPV4
knockdown 3T3-F442A adipocytes. These included Mcp1,
Mip1a, Mcp3, Rantes, and Vcam. These genes were expressed
at very low levels in the adipose tissues of lean animals, and no
significant differences were observed between the mutants and
controls on a chow diet (Figure 5F).with or without 48 hr GSK1016790A treatment (100 nM).
medium from adipocytes in (C) were determined by ELISA.
g adipocytes with shTRPV4 or shGFP; ##p < 0.01 and ###p < 0.001, comparing
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Figure 4. ERK1/2 Mediates the Signal Transduction from TRPV4 to Gene Expression
(A) 3T3-F442A adipocyteswith shTRPV4 or shGFPwere treatedwith 100 nMGSK1016790A for the indicated time, and cell lysateswere analyzed bywestern blot.
CL316243 (10 mM, 20 min) was used as a positive control for the detection of p38 phosphorylation.
(B) Adipocytes were exposed to 100 nM GSK1016790A or 50 ng/ml TNFa for 15 min in regular or calcium-free DMEM.
(C) Adipocytes were exposed to 100 nM GSK1016790A for 15 min with 45 min pretreatments of vehicle (GSK101+V), 10 mM U0126 (GSK101+U), or 10 mM
SP600125 (GSK101+SP).
(D) mRNA expression of Pgc1a, Mip1a, and Cxcl1 were analyzed 48 hr after the treatment.
Data are presented as mean ±SD.To further understand the role of TRPV4 under metabolic
stress, we challenged these mice with a high-fat diet (HFD)
that would induce obesity and provoke adipose inflammation.
There was no significant body weight difference between the
Trpv4/ and control mice until the animals were on the HFD
for 9 weeks (Figure 5A). Male and female mice showed a similar
pattern of weight gain (Figure S4A).
The adipose tissues were first examined after 8 weeks of
HFD, before the body weight of Trpv4/ mice diverged from
controls. Although the HFD tended to blunt the difference in
thermogenic gene expression, SubQ fat from the Trpv4/
animals expressed higher levels of these genes (Figure S4B).
Histological analysis showed that mutant mice have smaller
and more UCP1-positive adipocytes compared to controls
(Figure 4E).
Eight weeks of the HFD significantly elevated the mRNA
expression of proinflammatory chemokines in EPI fat in WT
mice, such as Mcp1, Mip1a, Rantes, and Mcp3, compared to
animals on a chow diet. Interestingly, without a difference in102 Cell 151, 96–110, September 28, 2012 ª2012 Elsevier Inc.adiposity at this time point, Trpv4/mice showed a substantial
decrease in the mRNA expression of Mcp1, Mip1a, and Mcp3
(Figure 5F). Similarly, the induction of those genes in the SubQ
fat was blunted in the Trpv4/ mice (Figure S4E).
As exposure to the HFD extended to 16 weeks, there was no
longer a difference in Ucp1 mRNA between the Trpv4/ and
control animals. However, the Trpv4/ mice still had elevated
expression of mRNAs encoding Adrb3 and Pgc1a in both the
SubQ and EPI depots (Figures S4C and S4D). Chemokine
expression in EPI fat continued to rise in WT mice. The expres-
sion of mRNAs for Mip1a and Vcam remained low in the
Trpv4/ mice, but the differences in Mcp1 and Mcp3 were
blunted (Figure 5F).
Because the Trpv4/ mice have a whole-body TRPV4 defi-
ciency, we asked whether the phenotype observed in vivo was
associated with cell-autonomous alterations in adipocytes. To
examine this, stromal-vascular cells from the adipose tissue of
young, lean Trpv4/ and WT mice were isolated and stimulated
to differentiate into adipocytes in vitro. After 8 days, greater
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Figure 5. Altered Thermogenic and Proinflammatory Programs in Trpv4/ Adipose Tissue
(A–D) (A) Body weights of WT and Trpv4/ mice on chow and HFD. mRNA expression of thermogenic genes (B), PGC1a protein (C), and UCP1 protein (D) in
SubQ fat from chow-fed mice.
(E) Representative images from immunohistochemistry for UCP1 (brown stain) in SubQ fat after 8 weeks of HFD. UCP1-expressing cells are indicated by arrows.
(F) mRNA expression of chemokines in EPI fat was analyzed under three diet conditions.
(G) Thermogenic gene expression and (H) chemokines and Tnfa mRNA expression in Trpv4/ and WT primary adipocytes.
Data are presented as mean ±SEM. See also Figures S4 and S5.than 90% of the cells were fully differentiated. Compared to
those fromWT controls, adipocytes from Trpv4/mice showed
elevated mRNA expression for ‘‘browning’’ gene program (Fig-ure 5G). Importantly, they had much greater induction in terms
of Pgc1a and Ucp1 expression in response to norepinephrine.
Conversely, the mRNA expression of proinflammatory genes,Cell 151, 96–110, September 28, 2012 ª2012 Elsevier Inc. 103
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such asMcp1,Mip1a,Mcp3, Tnfa, and Vcam, were substantially
reduced in Trpv4/ adipocytes (Figure 5H).
Moreover, we analyzed other metabolically active tissues and
organs, including interscapular brown fat, skeletal muscle, and
liver; minimal changes in expression of genes of oxidative
metabolism were observed in these tissues between the WT
and Trpv4/ mice (Figures S5A–S5C). Together, these data
indicate that TRPV4 controls key gene expression programs in
adipocytes in an apparently cell-autonomous manner.
Increased Energy Expenditure Protects TRPV4-
Deficient Mice from Diet-Induced Obesity
The TRPV4 mutant mice began to gain significantly less weight
after 9 weeks on the HFD compared to WT controls. Body
composition analysis showed that Trpv4/ mice had gained
less fat mass compared to controls (Figure 6A).
Energy expenditure (EE) in these mice was measured after
7 weeks of HFD, before the body weight of mutants diverged
from controls. By normalizing oxygen consumption to body
weight (Figure6B)orbyanalysisof covariance (ANCOVA) (Tscho¨p
et al., 2012) using body weight and genotype as covariance (p =
0.02 for genotype effect, Table S2), a highly significant increase
in EE was observed in the Trpv4/ mice compared to WT
controls. Importantly, there was no significant difference in food
intake, physical activity, or body temperature between the two
groups (Figures S6A–S6C). Together, these data strongly sug-
gest that the reduced weight gain upon HFD in Trpv4/ mice
was due, at least in part, to an increased EE associated with an
elevated thermogenic gene program in thewhite adipose tissues.
Trpv4/ Mice Have Reduced Inflammation in Adipose
Tissue and Improved Insulin Sensitivity
Obesity is associated with chronic ‘‘metainflammation’’ in
adipose tissue (Hotamisligil, 2006). Although the causes of the
recruitment of immune cells have not been well understood,
elevated chemokine expression has been suggested to be
critical for the development of inflammation and insulin resis-
tance (Sell and Eckel, 2009).
To understand the impact of the changes in chemokine gene
expression caused by TRPV4 deficiency, we analyzed the
expression of macrophage markers (F4/80, CD68, and CD11b)
to quantify the macrophage infiltration in Trpv4/ and WT
adipose tissues from all three diet groups. As expected, HFD
increased the expression of macrophage markers in WT adipose
tissue (Figure 6C), indicating that macrophages were actively re-
cruited into adipose tissues. Consistent with the reduction in
chemokine expression, Trpv4/ adipose tissue showed a 40Figure 6. Trpv4/ Mice Are Protected from Obesity, Adipose Inflamm
(A) Body composition in WT and Trpv4/ mice.
(B) Energy expenditure (as oxygen consumption) after 7 weeks of HFD.
(C) mRNA expression of macrophage markers.
(D) Hematoxylin and eosin staining (H&E) of EPI fat after 16 weeks of HFD; arrow
(E) Western blot analysis of PPARg serine-273 phosphorylation in EPI fat.
(F) Tnfa mRNA expression in EPI fat.
(G) Fasting and glucose (1 g/kg) stimulated insulin levels.
(H) IP-glucose tolerance test (1.0 g/kg) and (I) IP-insulin tolerance test (1 U/kg) in
Data are presented as mean ±SEM. See also Figure S6.or 60% reduction in the expression of the macrophage marker
after 8 or 16 weeks of HFD, respectively (Figure 6C). Indeed,
histologic analysis also showed that there were far fewer
‘‘crown-like structures’’—which were previously shown to repre-
sent macrophages in fat tissues (Cinti et al., 2005)—in the
Trpv4/ adipose tissues (Figure 6D). Importantly, macrophages
from Trpv4/ mice did not have altered program of gene
expression either at the basal level or in response to lipopolysac-
charides (LPS) or free fatty acid (Figures S6D and S6E); this
strongly suggests that the difference in macrophage infiltration
in adipose tissues was likely due to the altered adipocyte func-
tion rather than alterations in the macrophages per se.
To further assess the inflammation in adipose tissues, the
mRNA expression of Tnfa, a key cytokine for obesity-induced
insulin resistance, was measured. HFD significantly increased
Tnfa mRNA in WT adipose tissue, whereas the induction was
largely reduced in Trpv4/mice (Figure 6F). Furthermore, phos-
phorylation of serine 273 on PPARg, a modification that is asso-
ciated with obesity and insulin resistance (Choi et al., 2010), was
strongly attenuated in the Trpv4/ adipose tissue compared to
WT controls (Figure 6E).
Adipose inflammation is associated with insulin resistance.
Consistent with the changes in inflammatory markers, Trpv4/
micehave improved insulin sensitivity, as indicatedby the reduced
fastingandglucose-stimulated insulin levels (Figure6G), aswell as
an improved glucose tolerance (Figure 6H) compared to WT
controls. We also observed an improved insulin tolerance (Fig-
ure 6I) in the Trpv4/mice. Importantly, these changes preceded
the alterations in body weight (Figures S6F and S6G).
Pharmacological Inhibition of TRPV4 Modulates an
Adipose Gene Program and Improves Glucose
Homeostasis In Vivo
The role of TRPV4 in adipose energy metabolism and inflamma-
tion makes it a potential target for obesity and insulin resistance.
We used theTRPV4 antagonist GSK205 (Phan et al., 2009) to test
whether pharmacological modulation of TRPV4 could provide
metabolic benefits in a mouse model of obesity and insulin
resistance.
GSK205 potently antagonized TRPV4 in 3T3-F442A adipo-
cytes, as it effectively blocked the calcium influx caused by
TRPV4 agonist (Figure 7A). Treating these adipocytes with
GSK205 for 4 days resulted in increased expression of thermo-
genic genes (Figure 7B) and was also accompanied by a
decrease in the proinflammatory gene program. This shift resem-
bled the gene expression changes seen in TRPV4-deficient
adipocytes.ation, and Metabolic Dysfunction with Exposure to High-Fat Diet
s indicate ‘‘crown-like structures.’’
WT and Trpv4/ mice after 12 weeks of HFD.
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Figure 7. TRPV4 Antagonist Modulates an Adipose Gene Program and Improves Glucose Homeostasis In Vivo
(A) Intracellular Ca2+ measurement in 3T3-F442A cells in response to 100 nM GSK101 (agonist, arrowhead), with (n = 13) or without (n = 12) 10 mM TRPV4
antagonist GSK205.
(B andC) (B) ThemRNA expression of thermogenic and proinflammatory genes in GSK205- (5 mM) treated 3T3-F442A adipocytes and (C) in EPI fat fromGSK205-
treated animals.
(D) IP-glucose tolerance test (1 g/kg) in GSK205 or vehicle-treated DIO mice.
Data are presented as mean ±SEM. See also Figure S7.
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GSK205 has a relatively short half-life of 2 hr in the plasma and
adipose tissues (Figure S7A). As proof of principle, we treated
diet-induced obese (DIO) mice with 10 mg/kg GSK205 or vehicle
twice daily for a short period (7 days). The compound was rela-
tively well tolerated, as there were no apparent signs of sickness
or weight loss in either group during this period (Figure S7B).
Compared to controls, GSK205-treated mice showed signifi-
cantly increased expression of thermogenic genes such as
Ucp1, Pgc1a, Cidea, and Cox8b. Drug treatment also caused
a reduced expression of the proinflammatory chemokines,
macrophage marker, and Tnfa (Figure 7C) in the EPI fat. These
changes largely recapitulated the molecular phenotypes seen
in the Trpv4/ mice. A less significant trend in the expression
of these genes was observed in the SubQ fat (Figure S7C). In
contrast, no significant change was observed in the interscapu-
lar BAT (Figure S7D). Consistent with these gene expression
changes, strikingly, this short-term GSK205 treatment signifi-
cantly improved glucose tolerance in DIO mice compared to
controls (Figure 7D).
DISCUSSION
Adipocytes play a number of key roles in systemic energy
balance and metabolic regulation. First, white adipocytes are
the primary depot for energy storage inmammals. This important
function is highlighted in the tissue steatosis and illnesses that
occur in individuals with lipodystrophy. Second, in the context
of obesity, where energy intake chronically outstrips energy
expenditure, adipocytes become enlarged and adipose tissue
becomes inflamed. This was first recognized as a greatly
increased expression of TNFa and other cytokines in rodent
models of obesity (Hotamisligil et al., 1993). Although it was orig-
inally believed that fat cells themselves made these cytokines, it
is now appreciated that most of the secretion of these molecules
comes from immune cells, especially macrophages, that infil-
trate adipose tissue in elevated numbers in obesity (Weisberg
et al., 2003; Xu et al., 2003). Hence, a critical question now is
what are the physiological and pathological signals secreted
by fat cells that regulate the infiltration and function of these
immune cells? Finally, brown adipocytes are an important
component in whole-body energy homeostasis through the
dissipation of stored chemical energy in the form of heat. The
role of brown fat as a defense against both hypothermia and
obesity, at least in rodents, is well established (Feldmann et al.,
2009; Lowell et al., 1993). Adult humans have significant depots
of brown fat, but the contribution made by these deposits to total
energy metabolism is not known.
Despite both being important for obesity and related diseases,
thermogenesis and inflammation are ordinarily considered as
two separate aspects of adipose biology. As a common medi-
ator for both programs, TRPV4 is one of the first examples indi-
cating that these two programs are connected at the molecular
and physiological levels. Moreover, the striking changes of
chemokine gene expression in an adipocyte cell line (Figure 3A)
suggest that signaling from TRPV4 could serve as an early trigger
of immune cell chemoattraction. Hence, the convergence of
thermogenesis and inflammation identified here not only sug-
gests an angle for targeting obesity but also provides a perspec-tive on understanding the origin of adipose inflammation and
insulin resistance.
It is interesting that TRPV4 has been shown to be activated by
cellular swelling (Liedtke et al., 2000; Strotmann et al., 2000) and
by cellular stretch (Gao et al., 2003; Mochizuki et al., 2009;
Thodeti et al., 2009). Because adipocytes become very large in
obesity, it is possible that this cellular distention activates
TRPV4 and leads to the changes in gene programs. The precise
mechanisms by which TRPV4 signals are obscure, but it is clear
that ERK1/2 activation is very important for the effects.
TRPV4 deficiency protected mice from diet-induced obesity
and insulin resistance. Although the animals studied here have
a global Trpv4 deletion, there are several reasons to believe
that white adipose tissues contribute significantly to the pheno-
types. First, the gene expression changes in Trpv4/ adipose
tissue largely recapitulated what we observed in cultured adipo-
cytes, andmany of those changes preceded metabolic interven-
tion and the difference in physiological parameters. In contrast,
minimal differences in these key metabolic pathways were
observed in other metabolically active organs (liver and muscle)
in the same time frame (Figures S5A–S5C). These data strongly
suggest that the phenotypes seen in white adipose tissue are
unlikely to be secondary to those organs. However, with current
data, we certainly cannot exclude potential contributions from
the central nervous system (CNS) and the sympathetic nervous
system in particular. Also, it is interesting that a very recent study
of Trpv4/ mice has also shown a resistance to diet-induced
obesity (Kusudo et al., 2012). Although this paper did not
examine adipose tissues in detail, they showed alterations in
muscle biology and fiber-type switching in the soleus muscle.
It is not clear how this could affect energy balance and obesity,
but the role of TRPV4 in multiple tissues will be important for
future studies.
Our proof-of-principle study suggests that pharmacologic
inhibition of TRPV4 leads to an elevation of the thermogenic
gene program and a reduction in adipose tissue inflamma-
tion—both of which could provide therapeutic benefits for
obesity and metabolic diseases. Although TRPV4 is highly ex-
pressed in fat, it is also expressed in many other tissues
and has been implicated in osmotic regulation (Liedtke and
Friedman, 2003), bone formation (Masuyama et al., 2008), and
bladder dysfunction (Gevaert et al., 2007). Hence, the size of
the therapeutic window of TRPV4 antagonists in metabolic
diseases may depend on those functions. In particular, several
TRPV4 mutations associated with neurodegenerative disease
have been recently identified in humans (Jia et al., 2010; Land-
oure´ et al., 2010; Phelps et al., 2010). Further characterization
on the nature of these mutations would be valuable in deter-
mining the therapeutic value of TRPV4 antagonists.
It should be considered that other closely related TRPVs, such
as TRPV1, may also regulate one or both pathways controlled by
TRPV4 in fat. Several reports have suggested that TRPV1 and
TRPM8 could affect adipose function (Ma et al., 2012; Motter
and Ahern, 2008; Zhang et al., 2007). Nonetheless, the fact that
the genetic ablation and chemical inhibition of TRPV4 has a cell-
autonomous effect on both thermogenic and proinflammatory
programs in white adipocytes in vivo makes TRPV4 in particular
a very promising target for treating obesity and type 2 diabetes.Cell 151, 96–110, September 28, 2012 ª2012 Elsevier Inc. 107
EXPERIMENTAL PROCEDURES
Materials
Antibody sources are as follows: UCP1, tubulin and OXPHOS (Abcam), TRPV4
(Alomone), p-ERK1/2, ERK1/2, p-JNK, JNK, p-p38, p38 (Cell Signaling), and
PGC1a (Calbiochem). BCTCwas from Tocris. SLV319, CAY10508, and rosigli-
tazone were from Cayman. U0126 and SP600125 were from Cell Signaling.
GSK205 was synthesized at the Scripps Research Institute. Other chemicals
are from Sigma. shRNA constructs were in pLKO vectors or pMKO vectors.
Calcium-free DMEMwas made by adding 2.5 mM EGTA into DMEM (Cellgro).
Sequences for all shRNA and primers are listed in Table S3.Chemical Screen
Briefly, after 2 days of differentiation, 3T3-F442A adipocytes were trypsinized
and split into 384 well plates (3,000 cell/well). At day 6, cells were treated with
the bioactive library (Broad Institute) for 20 hr. mRNA was harvested by using
the TurboCapture kit (QIAGEN), which was reverse transcribed to cDNA and
quantified by qPCR. All values were normalized to DMSO-treated cells.Animals
All animal experiments were performed according to procedures approved by
the IACUC of Dana-Farber Cancer Institute. Mice were on a standard chow or
a 60%high-fat diet (ResearchDiets) with 12 hr light cycles. Trpv4/micewere
provided by Dr. Liedtke and backcrossed to C57BL/6J background. Unless
specified, male mice were used for experiments. Each group contains 9–16
animals. For drug treatment, C57BL/6J mice were on HFD for 14–15 weeks
before treatment. GSK205 (in DMSO) was dissolved in a vehicle contains
5% Tween80 and 90% saline before intraperitoneal injection. Each group
contains 10–12 mice, and experiments were performed twice in independent
cohorts.Metabolic Phenotyping
For glucose tolerance tests, animals were fasted overnight. Glucose levels in
tail blood were measured with a standard glucometer prior to and at indicated
intervals following an intraperitoneal injection of D-glucose. For insulin toler-
ance tests, animals were fasted for 4 hr before experiments. Fat and lean
mass were measured by MRI. Energy expenditure was evaluated by using
a Comprehensive Lab Animal Monitoring System (Columbia Instruments).
Mice were acclimated in the metabolic chambers for 2 days before the exper-
iments. CO2 and O2 levels were collected every 32 min for each mouse during
a period of 2 days and were normalized to total body weight. Movement and
food intake are measured more frequently at regular intervals.Cell Culture
For virus production, 293T (for lentivirus) or phoenix cells (retrovirus) were
transfected with Fugene 6 (Roche) with viral vectors. Viral supernatant was
harvested 48 hr later. 3T3-F442A preadipocytes were infected for 4 hr (lenti)
or overnight (retro), followed by puromycin selection (2 mg/ml). 3T3-F442A
adipocyte differentiation was induced by treating confluent cells with
850 nM insulin for 8–10 days. To stimulate thermogenesis, cells were incu-
bated with norepinephrine for 4 hr. For primary adipocytes, stromal vascular
fractions (SVF) from inguinal fat of 5-week-old male mice were prepared and
differentiated for 8 days as previously described (Kajimura et al., 2009).Statistics
Student’s t test was used for single comparisons. Two-way ANOVA (repeated
measurement) was used for GTT and ITT. Unless specified, *p < 0.05,
**p < 0.01, ***p < 0.001, and not significant (n.s.) p > 0.05.ACCESSION NUMBERS
The GEO accession number for the microarray data reported in this paper is
GSE40280.108 Cell 151, 96–110, September 28, 2012 ª2012 Elsevier Inc.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and three tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2012.08.034.
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